Chalene Johnson breaks down retatrutide, the peptide everyone is calling a GLP-3 and an Ozempic killer, cutting through the hype to get to what the science actually says. Eli Lilly's own clinical trials show weight loss results that beat anything semaglutide or tirzepatide has produced, but retatrutide is not FDA approved and is not legally available at any US pharmacy, which means almost nobody buying it online is actually getting the real thing.
Chalene explains what retatrutide actually is (a triple agonist that adds glucagon receptor activity to the GLP-1 and GIP receptors already targeted by Ozempic, Wegovy, Mounjaro, and Zepbound), walks through what the phase three trial data really shows versus how it is being exaggerated online, and shares why an independent lab test of vials sold through TikTok, med spas, and Reddit found most contained only 7 to 14 percent of anything resembling the real molecule.
She also unpacks the muscle preservation claims that are not backed by human data, the anhedonia and placebo effect reports circulating online, why bariatric surgery comparisons need context, and how to find a reputable source like Midi Health for anyone considering a GLP-1 through legitimate medical channels.
Topics discussed: retatrutide, Ozempic, semaglutide, Wegovy, tirzepatide, Mounjaro, Zepbound, GLP-1, GLP-3, Eli Lilly, bariatric surgery, Midi Health, anhedonia, muscle wasting, peptides, BPC 157
Go Beyond The Podcast Join Chalene on her private podcast 👉chalene.com/more
Book your virtual visit today with MIDI Health! For ALL your Testosterone and Hormone needs! 👉chalene.com/test
🚨Questions Chalene Wants Your Thoughts on:
Related Links:
Related Episodes:
Join the PodSquad on Facebook! 👉https://www.facebook.com/groups/ChalenePodSquad
We would love to hear from you! Leave your questions or messages for Chalene RIGHT HERE
To advertise on our podcast, please reach out to thechaleneshow@gmail.com and mention The Chalene Show
Connect with me on your fav social platform: